<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722371</url>
  </required_header>
  <id_info>
    <org_study_id>0431-102</org_study_id>
    <secondary_id>2008_522</secondary_id>
    <nct_id>NCT00722371</nct_id>
  </id_info>
  <brief_title>MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration
      in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2008</start_date>
  <completion_date type="Actual">March 25, 2011</completion_date>
  <primary_completion_date type="Actual">October 26, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C represents the percentage of glycosylated hemoglobin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
    <description>A1C represents the percentage of glycosylated hemoglobin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour PMG at Week 54</measure>
    <time_frame>Baseline and Week 54</time_frame>
    <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1615</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin phosphate</intervention_name>
    <description>Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 45 mg</arm_group_label>
    <other_name>Januvia</other_name>
    <other_name>Tesavel</other_name>
    <other_name>Xelevia</other_name>
    <other_name>Ristaben</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone hydrochloride</intervention_name>
    <description>Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.</description>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 45 mg</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo to sitagliptin</intervention_name>
    <description>Matching placebo to sitagliptin orally once daily for 54 weeks.</description>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo to pioglitazone</intervention_name>
    <description>Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 15 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 30 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg/ Pioglitazone 45 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is highly unlikely to conceive

          -  Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA)
             therapies, or is non-naïve based upon the patient's current diet, medical regimen and
             screening A1c patient is currently not on AHA with a screening A1c &gt;=7.5 % and =&lt;11.0
             % patient is currently on either metformin pr sulfonylurea monotherapy with a
             screening A1c &gt;=7.0 % and =&lt;9.0 %

        Exclusion Criteria

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has
             C=peptide value of =&lt;0.8 ng/mL

          -  Patient has previously been treated with insulin, thiazolidinedione (TZD)
             (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor
             (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a
             clinical study with any DPP-4 inhibitor or incretin mimetic

          -  Patient is on a weight loss program and is not in the maintenance phase or has started
             a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks

          -  Patient has undergone surgery within the prior 30 days or has major surgery planned
             during the study

          -  Patient has a medical history of active liver disease including chronic active
             hepatitis B or C or symptomatic gallbladder disease including primary biliary
             cirrhosis

          -  Patient has received treatment with an investigational product within 12 weeks prior
             to Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, Langdon RB, Kaufman KD, Steinberg H, Goldstein BJ. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. Diabetes Obes Metab. 2014 Mar;16(3):223-30. doi: 10.1111/dom.12194. Epub 2013 Aug 29.</citation>
    <PMID>23909985</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>September 9, 2011</results_first_submitted>
  <results_first_submitted_qc>September 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2011</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone 15 mg</title>
          <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="230"/>
                <participants group_id="P3" count="233"/>
                <participants group_id="P4" count="230"/>
                <participants group_id="P5" count="230"/>
                <participants group_id="P6" count="231"/>
                <participants group_id="P7" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="168"/>
                <participants group_id="P4" count="167"/>
                <participants group_id="P5" count="182"/>
                <participants group_id="P6" count="178"/>
                <participants group_id="P7" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="51"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Contraindication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine / Creatinine clearance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypoglycemia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone 15 mg</title>
          <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
            <count group_id="B2" value="230"/>
            <count group_id="B3" value="233"/>
            <count group_id="B4" value="230"/>
            <count group_id="B5" value="230"/>
            <count group_id="B6" value="231"/>
            <count group_id="B7" value="230"/>
            <count group_id="B8" value="1615"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="68"/>
                    <measurement group_id="B8" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 to 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="87"/>
                    <measurement group_id="B8" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="51"/>
                    <measurement group_id="B8" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="96"/>
                    <measurement group_id="B7" value="95"/>
                    <measurement group_id="B8" value="703"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="118"/>
                    <measurement group_id="B6" value="135"/>
                    <measurement group_id="B7" value="135"/>
                    <measurement group_id="B8" value="912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</title>
        <description>A1C represents the percentage of glycosylated hemoglobin.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set with last observation carried forward (LOCF). Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 24</title>
          <description>A1C represents the percentage of glycosylated hemoglobin.</description>
          <population>Full Analysis Set with last observation carried forward (LOCF). Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>Percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="171"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" lower_limit="-1.29" upper_limit="-0.89"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-1.09" upper_limit="-0.68"/>
                    <measurement group_id="O3" value="-1.21" lower_limit="-1.41" upper_limit="-1.02"/>
                    <measurement group_id="O4" value="-1.20" lower_limit="-1.40" upper_limit="-1.00"/>
                    <measurement group_id="O5" value="-1.53" lower_limit="-1.73" upper_limit="-1.34"/>
                    <measurement group_id="O6" value="-1.63" lower_limit="-1.82" upper_limit="-1.43"/>
                    <measurement group_id="O7" value="-1.81" lower_limit="-2.00" upper_limit="-1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24</title>
          <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="189"/>
                <count group_id="O6" value="181"/>
                <count group_id="O7" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" lower_limit="-32.0" upper_limit="-16.5"/>
                    <measurement group_id="O2" value="-19.5" lower_limit="-27.2" upper_limit="-11.7"/>
                    <measurement group_id="O3" value="-29.9" lower_limit="-37.6" upper_limit="-22.3"/>
                    <measurement group_id="O4" value="-37.4" lower_limit="-45.1" upper_limit="-29.7"/>
                    <measurement group_id="O5" value="-41.0" lower_limit="-48.5" upper_limit="-33.5"/>
                    <measurement group_id="O6" value="-46.9" lower_limit="-54.6" upper_limit="-39.3"/>
                    <measurement group_id="O7" value="-52.0" lower_limit="-59.6" upper_limit="-44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24</title>
        <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24</title>
          <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
          <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="136"/>
                <count group_id="O5" value="149"/>
                <count group_id="O6" value="143"/>
                <count group_id="O7" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.1" lower_limit="-64.0" upper_limit="-38.2"/>
                    <measurement group_id="O2" value="-30.6" lower_limit="-44.0" upper_limit="-17.3"/>
                    <measurement group_id="O3" value="-52.5" lower_limit="-64.9" upper_limit="-40.2"/>
                    <measurement group_id="O4" value="-66.6" lower_limit="-79.8" upper_limit="-53.5"/>
                    <measurement group_id="O5" value="-69.2" lower_limit="-81.7" upper_limit="-56.7"/>
                    <measurement group_id="O6" value="-85.5" lower_limit="-98.4" upper_limit="-72.6"/>
                    <measurement group_id="O7" value="-93.8" lower_limit="-106.4" upper_limit="-81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 54</title>
        <description>A1C represents the percentage of glycosylated hemoglobin.</description>
        <time_frame>Baseline and Week 54</time_frame>
        <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 54</title>
          <description>A1C represents the percentage of glycosylated hemoglobin.</description>
          <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>Percent of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="171"/>
                <count group_id="O5" value="179"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" lower_limit="-1.15" upper_limit="-0.72"/>
                    <measurement group_id="O2" value="-0.74" lower_limit="-0.96" upper_limit="-0.53"/>
                    <measurement group_id="O3" value="-1.16" lower_limit="-1.37" upper_limit="-0.95"/>
                    <measurement group_id="O4" value="-1.23" lower_limit="-1.45" upper_limit="-1.02"/>
                    <measurement group_id="O5" value="-1.45" lower_limit="-1.65" upper_limit="-1.24"/>
                    <measurement group_id="O6" value="-1.49" lower_limit="-1.71" upper_limit="-1.28"/>
                    <measurement group_id="O7" value="-1.78" lower_limit="-1.99" upper_limit="-1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 54</title>
        <time_frame>Baseline and Week 54</time_frame>
        <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 54</title>
          <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="181"/>
                <count group_id="O5" value="189"/>
                <count group_id="O6" value="181"/>
                <count group_id="O7" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" lower_limit="-21.6" upper_limit="-4.5"/>
                    <measurement group_id="O2" value="-10.5" lower_limit="-19.0" upper_limit="-2.0"/>
                    <measurement group_id="O3" value="-24.0" lower_limit="-32.4" upper_limit="-15.5"/>
                    <measurement group_id="O4" value="-33.3" lower_limit="-41.8" upper_limit="-24.8"/>
                    <measurement group_id="O5" value="-33.9" lower_limit="-42.2" upper_limit="-25.7"/>
                    <measurement group_id="O6" value="-37.1" lower_limit="-45.5" upper_limit="-28.6"/>
                    <measurement group_id="O7" value="-47.8" lower_limit="-56.1" upper_limit="-39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour PMG at Week 54</title>
        <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
        <time_frame>Baseline and Week 54</time_frame>
        <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 15 mg</title>
            <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Pioglitazone 45 mg</title>
            <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
            <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour PMG at Week 54</title>
          <description>PMG was measured using the Meal Tolerance Test (MTT).</description>
          <population>Full Analysis Set with LOCF. Reasons for exclusion included no baseline data and/or no post-baseline data.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="143"/>
                <count group_id="O7" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" lower_limit="-50.2" upper_limit="-23.7"/>
                    <measurement group_id="O2" value="-26.7" lower_limit="-40.5" upper_limit="-13.0"/>
                    <measurement group_id="O3" value="-46.8" lower_limit="-59.6" upper_limit="-34.1"/>
                    <measurement group_id="O4" value="-58.2" lower_limit="-71.6" upper_limit="-44.7"/>
                    <measurement group_id="O5" value="-64.7" lower_limit="-77.6" upper_limit="-51.8"/>
                    <measurement group_id="O6" value="-69.7" lower_limit="-83.1" upper_limit="-56.4"/>
                    <measurement group_id="O7" value="-88.2" lower_limit="-101.2" upper_limit="-75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg and matching placebo to pioglitazone once daily for 54 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone 15 mg</title>
          <description>Pioglitazone 15 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Pioglitazone 45 mg</title>
          <description>Pioglitazone 45 mg and matching placebo to sitagliptin once daily for 54 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Sitagliptin 100 mg/ Pioglitazone 15 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 15 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Sitagliptin 100 mg/ Pioglitazone 30 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 30 mg once daily for 54 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Sitagliptin 100 mg/ Pioglitazone 45 mg</title>
          <description>Sitagliptin 100 mg and pioglitazone 45 mg once daily for 54 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="233"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="231"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="233"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="230"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="230"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="231"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="231"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E6" events="19" subjects_affected="15" subjects_at_risk="231"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="231"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="233"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="231"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="25" subjects_at_risk="231"/>
                <counts group_id="E2" events="30" subjects_affected="20" subjects_at_risk="230"/>
                <counts group_id="E3" events="78" subjects_affected="22" subjects_at_risk="233"/>
                <counts group_id="E4" events="81" subjects_affected="20" subjects_at_risk="230"/>
                <counts group_id="E5" events="45" subjects_affected="20" subjects_at_risk="230"/>
                <counts group_id="E6" events="100" subjects_affected="26" subjects_at_risk="231"/>
                <counts group_id="E7" events="93" subjects_affected="24" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="231"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="233"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E6" events="18" subjects_affected="14" subjects_at_risk="231"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="231"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="233"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="231"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

